title: Impact of empagliflozin on diabetic kidney disease.
abstract: Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule-glomerular feedback, thereby protect against diabetes-induced caidio-renal injuries.
authors.affiliation: Department of Diabetology & Endocrinology, Division of Anticipatory Molecular Food Science and Technology, Kanazawa Medical University, Ishikawa, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Koya
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C570240:empagliflozin